BETHLEHEM, Pa., July 22, 2013 /PRNewswire-iReach/ -- Saladax Biomedical, Inc., a privately held company developing novel diagnostic tests with the goals of improving health and positively impacting the economics of care, today announced the hiring of John McAuliffe as Vice President of Companion Diagnostics Business Development. Mr. McAuliffe has over 20 years' experience in healthcare serving in roles including drug development, sales, marketing and business development. Prior to joining Saladax, Mr. McAuliffe contributed to the success of Athena Diagnostics during his 13 year tenure by serving in various roles up to and including Director of Business Development, Neurology where he was responsible for management of biomedical research as well as the identification, evaluation and launch of over 100 protein and molecular diagnostic assays, which led to acquisition by Quest Diagnostics from Thermo Fisher Scientific in 2011. Mr. McAuliffe is a member of the American Academy of Neurology, the American Society of Human Genetics, holds a Bachelor Degree of Science, Pharmacology, from the University of California Santa Barbara and has contributed to various peer reviewed scientific publications.
"Mr. McAuliffe is an excellent sales and business development professional with an undergraduate degree in pharmacology, background in pharmaceutical sales, experience in Companion Diagnostic deals, and is knowledgeable and published in the Alzheimer's space. His focus will primarily be to develop and manage business collaborations on the Companion Diagnostics side of our business." said Kevin Harter, President and CEO.
About Saladax Biomedical, Inc.
Saladax Biomedical is a leader in the development and deployment of high quality diagnostic services and products, delivering actionable data to help physicians to select and optimize the use of current and new pharmaceutical products, with the goals of improving health and positively impacting the economics of care. Saladax also serves as a valuable collaborator for pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.
Media Contact: Lorraine Damico, MBA, Saladax Biomedical Inc., 484-547-0529, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Saladax Biomedical Inc.|
Copyright©2012 PR Newswire.
All rights reserved